![147886-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-07/147886-Thumbnail%20Image.png?versionId=EvnbvimC2YSIYo1HCKvQ78GFNHcr82WW&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240530/us-west-2/s3/aws4_request&X-Amz-Date=20240530T153819Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=c2615d5e46264b19639c9ebcd952b7a8779ca694fa57e05726c2b3fb7961a310&itok=R_2nyA8C)
The goal of this project was to design and create a genetic construct that would allow for <br/>tumor growth to be induced in the center of the wing imaginal disc of Drosophila larvae, the <br/>R85E08 domain, using a heat shock. The resulting transgene would be combined with other <br/>transgenes in a single fly that would allow for simultaneous expression of the oncogene and, in <br/>the surrounding cells, other genes of interest. This system would help establish Drosophila as a <br/>more versatile and reliable model organism for cancer research. Furthermore, pilot studies were <br/>performed, using elements of the final proposed system, to determine if tumor growth is possible <br/>in the center of the disc, which oncogene produces the best results, and if oncogene expression <br/>induced later in development causes tumor growth. Three different candidate genes were <br/>investigated: RasV12, PvrACT, and Avli.
![152291-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-08/152291-Thumbnail%20Image.png?versionId=iZ6C6s_k46N_QWqSoBwLWGxd_kBVU7Xv&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240530/us-west-2/s3/aws4_request&X-Amz-Date=20240530T153910Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=1303570ccef2b14edc8052719e2b84f62bc0a46c88a1d91d0e3ca7ce5ecb68cd&itok=8AbhFPqq)
![152247-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-08/152247-Thumbnail%20Image.png?versionId=O0eBpgBJ_lNVSd4by0.uUwI.xWwOm5Xw&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240601/us-west-2/s3/aws4_request&X-Amz-Date=20240601T062232Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=5534f506219a21f4014632fd72bcaf3d1bf9d024ce9e1e49ab6cf91b03592ce2&itok=AreXtG3v)
![152123-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-08/152123-Thumbnail%20Image.png?versionId=jMipKiYd4dPa.8xRup_4_6sAG31nRkZh&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240530/us-west-2/s3/aws4_request&X-Amz-Date=20240530T153824Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=effbadd8af959cd44bec92b372e118f8e8f4068810355af558f787698ae12a57&itok=tS72118i)
![150637-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-08/150637-Thumbnail%20Image.png?versionId=4G0VjWyaaEwTIo4zTGMl7QM5tlj_GEtv&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240614/us-west-2/s3/aws4_request&X-Amz-Date=20240614T235936Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=2a2b47e1515788ec54aadbd484998f09b802ceb633b8eb9d0b5156c69066021b&itok=Z8EOJrOT)
![150705-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-09/150705-Thumbnail%20Image.png?versionId=VvRzj2Xb3r.8QjEuR_Uvn6ULkjyFPyYa&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240614/us-west-2/s3/aws4_request&X-Amz-Date=20240614T144751Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=5a1232ca7080c9130e823ab3ce96ab065d9e1092d2e4db39fbd50df39a6b3564&itok=B9Uv7wHG)
![150711-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-09/150711-Thumbnail%20Image.png?versionId=UCXDDCK0Pl5uMSVduhodR.73siq6RPPt&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240530/us-west-2/s3/aws4_request&X-Amz-Date=20240530T153910Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=61de383fbbe70c59b72139483616cafb55a81905d6e753ceea5a396864537afb&itok=Q4QEKJu3)
![135905-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/135905-Thumbnail%20Image.png?versionId=kgi87RWNmMRtAhEtotiwJG09EMQv3_1_&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240530/us-west-2/s3/aws4_request&X-Amz-Date=20240530T153949Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=45d43abaa3d8f0ee93f9b8e0b436549ae01b3eb560cdf37d49fb326eec2cb683&itok=67V3tPhH)
![136699-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/136699-Thumbnail%20Image.png?versionId=GjI3qklHXyNC60P5PDeT66QeTbLfRXa1&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240614/us-west-2/s3/aws4_request&X-Amz-Date=20240614T144751Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=2ef038cab81c5e72776dc72864d3b8284058e2266bd560b1b108bb0452af6c48&itok=2xPveqje)
![136935-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/136935-Thumbnail%20Image.png?versionId=aUTdk4C1pX6WU6pL2oGcmKifq.utONV9&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240618/us-west-2/s3/aws4_request&X-Amz-Date=20240618T125225Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=615f2357f838f54d3fad13608fcfc587831491449fe0882730afeeddf1ef5683&itok=peuQNl6h)
The synergistic effects between Vorinostat and Tamoxifen observed through a phase II study on breast cancer patients resistant to hormone therapy may involve more than the modulation of ER-alpha to reverse Tamoxifen resistance in ERBC cells. RT-qPCR of genes expressed in Tamoxifen resistant cells, trefoil factor 1(TFF1) and v-myc avian myelocytomatosis viral oncogene homolog (MYC), were evaluated along with ESR1 and Diablo as a control. MYC was observed to have increased expression in the treated cells, whereas the other genes had a decrease in their expression levels after the cells were treated for 3 days with Vorinostat IC30 of 1 µM. As for targeting the AR, MCF7 Tamoxifen sensitive and resistant cells were not affected by the AR antagonists to determine an IC50. The cell viability for all MCF7 sub-clones only decreased for high concentrations of 5.56 µM - 50 µM in Bicalutamide and 16.67 µM – 50 µM of MDV1300. Furthermore, hormone depletion of MCF7 G11 Tamoxifen resistant sub-clones did not show a great response to DHT stimulation or the AR antagonists. In the RT-qPCR, the MCF7 G11 cells showed an increase in mRNA expression for ER, AR, and PR after 4 hours of treatment with estradiol. As for the DHT treatment, ER, AR, PR, and PSA had a minimal increase in the fold change, but the fold change in AR was less than in the estradiol treatment. The Mayo Clinic will investigate the possible usage of AR as a biomarker through immunohistochemistry.